170 related articles for article (PubMed ID: 37683266)
21. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
22. The vitreomacular interface in retinal vein occlusion.
Bertelmann T; Kičová N; Messerschmidt-Roth A; Irle S; Sekundo W; Mennel S
Acta Ophthalmol; 2011 Jun; 89(4):e327-31. PubMed ID: 21310017
[TBL] [Abstract][Full Text] [Related]
23. Vitreous Hyper-Reflective Dots in Optical Coherence Tomography and Retinal Tear in Patients with Acute Posterior Vitreous Detachment.
Oh JH; Oh J; Roh HC
Curr Eye Res; 2017 Aug; 42(8):1179-1184. PubMed ID: 28358220
[TBL] [Abstract][Full Text] [Related]
24. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
25. Role of the vitreous in posterior segment neovascularization in central retinal vein occlusion.
Akiba J; Kado M; Kakehashi A; Trempe CL
Ophthalmic Surg; 1991 Sep; 22(9):498-502. PubMed ID: 1945273
[TBL] [Abstract][Full Text] [Related]
26. THE IMPACT OF THE VITREOMACULAR INTERFACE ON FUNCTIONAL AND ANATOMICAL OUTCOMES IN DIABETIC MACULAR EDEMA TREATED WITH THREE DIFFERENT ANTI-VEGF AGENTS: Post Hoc Analysis of The Protocol T Study.
Mylonas G; Najeeb BH; Goldbach F; Deak GG; Michl M; Brugger J; Schmidt-Erfurth U; Gerendas BS
Retina; 2022 Nov; 42(11):2066-2074. PubMed ID: 35962998
[TBL] [Abstract][Full Text] [Related]
27. The effect of posterior vitreous detachment on aflibercept response in diabetic macular oedema.
Özsaygili C; Küçük B; Yildirim Y
Br J Ophthalmol; 2021 Jun; 105(6):800-805. PubMed ID: 32727727
[TBL] [Abstract][Full Text] [Related]
28. Retrospective analyses of optical coherence tomography in recurrent macular edema following intravitreal therapy in patients with retinal vein occlusion.
Holland SM; Dodwell DG; Krimmel DA; de Fiebre CM
BMC Ophthalmol; 2015 Sep; 15():117. PubMed ID: 26337708
[TBL] [Abstract][Full Text] [Related]
29. Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
JAMA Ophthalmol; 2022 May; 140(5):458-464. PubMed ID: 35323843
[TBL] [Abstract][Full Text] [Related]
30. The role of posterior vitreous detachment on the efficacy of anti-vascular endothelial growth factor intravitreal injection for treatment of neovascular age-related macular degeneration.
Neudorfer M; Fuhrer AE; Zur D; Barak A
Indian J Ophthalmol; 2018 Dec; 66(12):1802-1807. PubMed ID: 30451182
[TBL] [Abstract][Full Text] [Related]
31. Accuracy of Spectral-Domain OCT of the Macula for Detection of Complete Posterior Vitreous Detachment.
Hwang ES; Kraker JA; Griffin KJ; Sebag J; Weinberg DV; Kim JE
Ophthalmol Retina; 2020 Feb; 4(2):148-153. PubMed ID: 31864940
[TBL] [Abstract][Full Text] [Related]
32. FULL-THICKNESS MACULAR HOLE FORMATION AND SPONTANEOUS CLOSURE DURING INTRAVITREAL RANIBIZUMAB THERAPY FOR CENTRAL RETINAL VEIN OCCLUSION.
Goel N
Retin Cases Brief Rep; 2022 Nov; 16(6):678-680. PubMed ID: 33165304
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.
Iturralde D; Spaide RF; Meyerle CB; Klancnik JM; Yannuzzi LA; Fisher YL; Sorenson J; Slakter JS; Freund KB; Cooney M; Fine HF
Retina; 2006 Mar; 26(3):279-84. PubMed ID: 16508427
[TBL] [Abstract][Full Text] [Related]
34. Extrafoveal vitreous traction associated with branch retinal vein occlusion.
Ophir A; Trevino A; Martinez MR
Eur J Ophthalmol; 2010; 20(4):733-9. PubMed ID: 20099242
[TBL] [Abstract][Full Text] [Related]
35. The impact of posterior vitreous adhesion on ischaemia in eyes with retinal vein occlusion.
Bertelmann T; Kicova N; Mennel S; Schmidt J; Irle S; Sekundo W; Schulze S
Acta Ophthalmol; 2016 Feb; 94(1):e43-8. PubMed ID: 26290142
[TBL] [Abstract][Full Text] [Related]
36. Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration.
Waldstein SM; Coulibaly L; Riedl S; Sadeghipour A; Gerendas BS; Schmidt-Erfurth UM
Br J Ophthalmol; 2020 Jul; 104(7):899-903. PubMed ID: 31563866
[TBL] [Abstract][Full Text] [Related]
37. Spectral domain optical coherence tomography and B-scan ultrasonography in the evaluation of retinal tears in acute, incomplete posterior vitreous detachment.
Abdolrahimzadeh S; Piraino DC; Scavella V; Abdolrahimzadeh B; Cruciani F; Gharbiya M; Recupero SM
BMC Ophthalmol; 2016 May; 16():60. PubMed ID: 27215604
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the effects of aflibercept and dexamethasone in central retinal vein occlusion with serous retinal detachment.
Bayat AH; Akpolat Ç; Livan H; Bölükbaşı S; Elçioğlu MN
Clin Exp Optom; 2022 May; 105(4):404-409. PubMed ID: 34139964
[TBL] [Abstract][Full Text] [Related]
39. Ocriplasmin for symptomatic vitreomacular adhesion.
Neffendorf JE; Kirthi V; Pringle E; Jackson TL
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD011874. PubMed ID: 29040800
[TBL] [Abstract][Full Text] [Related]
40. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
